TrialNeuro-oncology2017

Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.

Juan Manuel Sepúlveda-Sánchez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.